P/E ratio for BiondVax (BVXV)
P/E ratio as of April 2024 (TTM): -0.3541
According to BiondVax's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.354121. At the end of 2022 the company had a P/E ratio of -0.7400.
P/E ratio history for BiondVax from 2016 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.7400 | -92.22% |
| 2021 | -9.51 | -87.65% |
| 2020 | -77.0 | 899.83% |
| 2019 | -7.70 | 53.46% |
| 2018 | -5.02 | -46.77% |
| 2017 | -9.42 | -46.11% |
| 2016 | -17.5 | 16.97% |
| 2015 | -15.0 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -3.70 | 946.01% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.